Vikram Mehra, MD
Psychiatry · Katy, TXNPI 1801848957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $902,309 of the $1,197,915 with a category attached, or 75.3%. 25 manufacturers reported payments, led by Alkermes, Inc. at 47.1% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,592 payments — averaging $462.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$564K
- Teva Pharmaceuticals USA, Inc.$146K
- E.r. Squibb & Sons, L.L.C.$140K
- Vanda Pharmaceuticals Inc.$96K
- Otsuka America Pharmaceutical, Inc.$94K
- Sunovion Pharmaceuticals Inc.$41K
- plus $116K from 19 others
Across 2 payments — averaging $878.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$78,2737%
- Speaking & faculty fees$902,30975%
- Travel & lodging$171,77914%
- Food & beverage$45,3584%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 845 | $564,493 |
| Teva Pharmaceuticals USA, Inc. | 310 | $145,867 |
| E.r. Squibb & Sons, L.L.C. | 211 | $140,078 |
| Vanda Pharmaceuticals Inc. | 207 | $95,854 |
| Otsuka America Pharmaceutical, Inc. | 266 | $94,198 |
| Sunovion Pharmaceuticals Inc. | 154 | $41,359 |
| Axsome Therapeutics, Inc. | 59 | $39,563 |
| Supernus Pharmaceuticals, Inc. | 77 | $34,848 |
| Neurocrine Biosciences, Inc. | 62 | $26,754 |
| Corium, LLC | 44 | $4,385 |
| Indivior Inc. | 40 | $2,507 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,887 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,620 |
| AbbVie(2 entities) | 108 | $1,549 |
| Lundbeck LLC | 64 | $1,299 |
| Johnson & Johnson | 24 | $554 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $356 |
| Eisai Inc. | 29 | $273 |
| Almatica Pharma LLC | 6 | $118 |
| Bausch Health US, LLC | 6 | $106 |
| Idorsia Pharmaceuticals US Inc | 6 | $105 |
| Avanir Pharmaceuticals, Inc. | 4 | $81 |
| Livanova USA, Inc. | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,197,915 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 98 | $329,904 |
| LybalviOlanzapine/Samidorphan Malate | 139 | $240,447 |
| Austedo XrDeutetrabenazine | 17 | $222,376 |
| IngrezzaValbenazine Tosylate | 14 | $118,341 |
| Invega SustennaPaliperidone Palmitate | 31 | $110,904 |
| RexultiBrexpiprazole | 45 | $76,328 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $45,225 |
| FanaptIloperidone | 18 | $38,488 |
| Lurasidone Hcl | 29 | $16,332 |
| TrintellixVortioxetine Hydrobromide | 19 | $14,487 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $12,500 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 215 | $8,418 |
| Lisdexamfetamine Dimesylate | 24 | $7,822 |
| Clozapine | 60 | $7,446 |
| Chlorpromazine Hcl | 38 | $7,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $564,493 | $570,351237 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $145,867 | $222,37617 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $26,754 | $118,34114 claims |
| Johnson & JohnsonInvega Sustenna | $554 | $110,90431 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $94,198 | $76,32845 claims |
| Axsome Therapeutics, Inc.Auvelity | $39,563 | $45,22541 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $95,854 | $38,48818 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $356 | $26,98645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Katy
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.